Aimmune Therapeutics' Palforzia, formerly called AR101, an oral immunotherapy indicated as a treatment for pediatric patients with peanut allergies, gained the backing of the FDA's Allergenic Products Advisory Committee in a 7-2 vote. The vote was made on the condition that clinicians will guarantee that patients prescribed Palforzia are also given a valid epinephrine autoinjector prescription in case those undergoing treatment experience systemic allergic reactions as per the FDA's prerequisite of a Risk Evaluation and Mitigation Strategy.
FDA committee backs Palforzia as peanut allergy treatment for kids
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.